Amgen and AbbVie Settle Adalimumab BPCIA Litigation

Goodwin
Contact

Amgen has announced that it has settled all pending patent litigation regarding AMJEVITA, its biosimilar version of AbbVie’s Humira® (adalimumab). Amgen reports that AbbVie will grant patent licenses for the use and sale of the product worldwide, on a country-by-country basis. Amgen states that it expects to launch its product in Europe on Oct. 16, 2018, and in the United States on Jan. 31, 2023.

The FDA approved AMJEVITA on September 23, 2016.  As we previously reported, AbbVie filed a BPCIA complaint against Amgen on August 4, 2016. AbbVie had asserted 10 patents as part of the first- wave litigation but, according to its complaint, had identified 51 other patents that it could assert against Amgen in a second-wave litigation. A 20-day bench trial was scheduled for November 4, 2019.

AbbVie’s BPCIA litigation against Boehringer Ingelheim (BI) regarding BI’s aBLA for a biosimilar version of Humira remains pending.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Goodwin

Written by:

Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide